RxDoctor Payments DataLook up a doctor →

Lloyd Norris, MD

Interventional Cardiology · Conway, ARNPI 1508825647

Payments from drug & device makers

$8,835in general payments, 2019–2025

Across 529 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$1K
  • Novartis$1K
  • Boehringer Ingelheim$979
  • Amgen$855
  • Merck$640
  • Johnson & Johnson$550
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$8,805100%
  • Education$310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,835 in reported general payments places this provider in the 55th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$285,806
Medicare patients
1,388
Services billed
5,580

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban885$632,080
EntrestoSacubitril/Valsartan276$212,838
XareltoRivaroxaban204$176,053
Repatha SureclickEvolocumab87$51,999
JardianceEmpagliflozin39$34,312
BrilintaTicagrelor27$12,683
Ranolazine ErRanolazine122$8,894
MultaqDronedarone Hcl11$8,792
Diltiazem 24hr Er (Cd)Diltiazem Hcl327$6,802
Atorvastatin Calcium696$5,323
Digoxin328$4,319
Prasugrel Hcl47$4,224
ClopidogrelClopidogrel Bisulfate470$3,444
Ezetimibe148$3,204
Potassium Chloride199$3,177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,307$632,080885 claims
NovartisEntresto$1,275$212,838276 claims
Johnson & JohnsonXarelto$550$176,053204 claims
Boehringer IngelheimJardiance$979$34,31239 claims
AstraZenecaBrilinta$206$12,68327 claims
Sanofi-aventis U.S. LLCMultaq$346$8,79211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →